- Home
- NKTX vs ADCT Comparison
NKTX vs ADCT Comparison
Compare NKTX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- ADCT
- Stock Information
- Founded
- NKTX 2015
- ADCT 2011
- Country
- NKTX United States
- ADCT Switzerland
- Employees
- NKTX N/A
- ADCT N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- ADCT Health Care
- Exchange
- NKTX Nasdaq
- ADCT Nasdaq
- Market Cap
- NKTX 170.8M
- ADCT 143.1M
- IPO Year
- NKTX 2020
- ADCT 2020
- Fundamental
- Price
- NKTX $2.05
- ADCT $1.63
- Analyst Decision
- NKTX Strong Buy
- ADCT Strong Buy
- Analyst Count
- NKTX 5
- ADCT 5
- Target Price
- NKTX $15.20
- ADCT $8.00
- AVG Volume (30 Days)
- NKTX 853.6K
- ADCT 493.2K
- Earning Date
- NKTX 03-20-2025
- ADCT 03-12-2025
- Dividend Yield
- NKTX N/A
- ADCT N/A
- EPS Growth
- NKTX N/A
- ADCT N/A
- EPS
- NKTX N/A
- ADCT N/A
- Revenue
- NKTX N/A
- ADCT $70,717,000.00
- Revenue This Year
- NKTX N/A
- ADCT $6.81
- Revenue Next Year
- NKTX N/A
- ADCT $11.23
- P/E Ratio
- NKTX N/A
- ADCT N/A
- Revenue Growth
- NKTX N/A
- ADCT N/A
- 52 Week Low
- NKTX $1.96
- ADCT $1.39
- 52 Week High
- NKTX $16.24
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- NKTX 39.74
- ADCT 46.49
- Support Level
- NKTX $1.96
- ADCT $1.55
- Resistance Level
- NKTX $2.35
- ADCT $1.73
- Average True Range (ATR)
- NKTX 0.15
- ADCT 0.12
- MACD
- NKTX -0.00
- ADCT 0.03
- Stochastic Oscillator
- NKTX 19.15
- ADCT 63.16
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.